Actively Recruiting
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Led by Asmaa Hassan mohamed Abdel Mawjoud · Updated on 2026-03-18
38
Participants Needed
2
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.
CONDITIONS
Official Title
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hematologic malignancies.
- Newly diagnosed patients.
You will not qualify if you...
- Patients with hematologic disorders other than hematologic malignancies.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Assiut University
Asyut, Egypt
Completed
2
Assiut university
Asyut, Egypt
Actively Recruiting
Research Team
A
asmaa H mohamed, R.DR
CONTACT
D
Dina A Mohareb, a.prof
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here